CDH2 and ovarian carcinoma: We confirmed the N-cadherin blocking action of the active compounds by showing they reduced N-cadherin abundance at intercellular contacts in N-cadherin expressing SKOV-3 ovarian cancer cell line (Tang et al., 2016).